Q-omics provides the consensus-scored BRD9P2 profile across patient tissues and cancer cell-line models. BRD9P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, BRD9P2 is differentially expressed in 9, with the highest sampling consensus in BLCA. Additionally, BRD9P2 RNA expression shows 15,312 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and BLCA as cancer lineages where BRD9P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BRD9P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BRD9P2 survival associations across molecular data types. BRD9P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BRD9P2 RNA expression–survival associations across cancer types. High BRD9P2 expression shows unfavorable associations in UVM, COAD and SKCM, but favorable associations in HNSC, LUAD and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for BRD9P2 RNA expression.
This table summarizes BRD9P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BRD9P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BRD9P2 shows lower tumor expression in BLCA, LUAD, THCA, LUSC, KIRP and UCEC. The BLCA box plot shows higher BRD9P2 RNA expression in normal versus tumor tissue (log2 FC = −1.149, t-test p < 0.001).
This table shows molecular features associated with BRD9P2 in patient tissues and cancer cell lines. In patient samples, BRD9P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
